RT Journal Article
A1 Stojkov, Igor
A1 Conrads-Frank, Annette
A1 Rochau, Ursula
A1 Arvandi, Marjan
A1 Koinig, Karin A.
A1 Schomaker, Michael
A1 Mittelman, Moshe
A1 Fenaux, Pierre
A1 Bowen, David
A1 Sanz, Guillermo F.
A1 Malcovati, Luca
A1 Langemeijer, Saskia
A1 Germing, Ulrich
A1 Madry, Krzysztof
A1 Guerci-Bresler, Agnès
A1 Culligan, Dominic J.
A1 Kotsianidis, Ioannis
A1 Sanhes, Laurence
A1 Mills, Juliet
A1 Puntscher, Sibylle
A1 Schmid, Daniela
A1 van Marrewijk, Corine
A1 Smith, Alexandra
A1 Efficace, Fabio
A1 de Witte, Theo
A1 Stauder, Reinhard
A1 Siebert, Uwe
T1 Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
JF Blood Advances
JO Blood Adv
YR 2023
DO 10.1182/bloodadvances.2022008360
VO 7
IS 12
SP 2772
OP 2783
SN 2473-9529
AB Patients with myelodysplastic syndromes (MDS) frequently experience a significant symptom burden, which reduces health-related quality of life (HRQoL). We aimed to identify determinants of low HRQoL in patients recently diagnosed with MDS, for guiding early intervention strategies. We evaluated longitudinal data in 2205 patients with MDS during their first year after diagnosis. Median values of EQ-5D 3-level (EQ-5D-3L) index (0.78) and visual analog scale (VAS) score (0.70) were used as thresholds for low HRQoL. In addition, the 5 dimensions of EQ-5D-3L were analyzed for impairments (any level vs “no problem” category). After multiple imputation of missing values, we used generalized estimating equations (GEE) to estimate odds ratios (OR) for univariable determinant screening (P < .15), and to subsequently derive multivariable models for low HRQoL with 95% confidence intervals (CI). Multivariable GEE analysis showed the following independent determinants (OR, 95% CI) for low EQ-5D index: increased age (60-75 years: 1.33, 1.01-1.75; >75: 1.84, 1.39-2.45), female sex (1.70, 1.43-2.03), high serum ferritin level (≥1000 vs ≤300 μg/L: 1.41, 1.06-1.87), comorbidity burden (per unit: 1.11, 1.02-1.20), and reduced Karnofsky performance status (KPS, per 10 units: 0.62, 0.58-0.67). For low VAS score, additional determinants were transfusion dependence (1.53, 1.03-2.29), low hemoglobin <10 g/dL (1.34, 1.12-1.61), and high body mass index (≥30 vs 23-29.9 kg/m2: 1.26, 1.02-1.57). Sex, KPS, comorbidity burden, hemoglobin count, and transfusion burden were determinants for all EQ-5D dimensions. Low HRQoL is determined by multiple factors, which should be considered in the management and shared decision making of patients with MDS. This trial was registered at www.clinicaltrials.gov as #NCT00600860.
RD 11/15/2025
UL https://doi.org/10.1182/bloodadvances.2022008360